Physician profile
Michael Becker
NPI 1992703920
$21,201.14
in general payments reported to CMS, 2019-2025
74 companies · $3,393 in 2025
The $3,393 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,826 · 2020: $2,682 · 2021: $3,441 · 2022: $2,657 · 2023: $3,127 · 2024: $3,075 · 2025: $3,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,578 · Education: $17.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,577.65 |
| Education | $17.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,969.67 | 2019-2025 | Nuplazid |
| Biogen, INC. | $1,400.97 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Abbvie INC. | $1,289.30 | 2019-2025 | Botox, Ubrelvy, Duopa |
| Ucb, INC. | $1,187.80 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Grifols USA, LLC | $1,067.49 | 2019-2025 | Gamunex-C |
| Amgen INC. | $864.68 | 2019-2025 | Uplizna, Aimovig |
| Csl Behring | $669.68 | 2019-2024 | Hizentra |
| Sk Life Science, INC. | $652.81 | 2020-2025 | |
| Lundbeck LLC | $640.27 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $591.95 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Genzyme Corporation | $560.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $555.00 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $554.21 | 2019-2022 | |
| Pfizer INC. | $531.29 | 2019-2025 | |
| Argenx US, INC. | $522.44 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.